Tag Archives: The Stem Cell Blog

CAR T cells more powerful when built with CRISPR, researchers find – Science Daily

Continue reading

2017-02-22 NEWS

Blasting News

CAR T cells more powerful when built with CRISPR, researchers find
Science Daily
“Cancer cells are relentless in their attempt to evade treatment, so we need CAR T cells that can match and outlast them,” explained Michel Sadelain, MD, PhD, senior author on the Nature paper and Director of the Center for Cell Engineering and the
CRISPR Genome-Editing Tool Takes Cancer Immunotherapy to the Next LevelMemorial Sloan Kettering Cancer Center (blog)

all 27 news articles »

Continue reading

2017-02-22 NEWS

Philadelphia Business Journal

Why Spark’s CEO says 2017 may be a ‘historic year’ for his gene therapy company
Philadelphia Business Journal
Philadelphia gene therapy company Spark Therapeutics said it is in the final stages of completing its rolling biologics license application for its lead product: a one-time treatment for an inherited retinal disease that causes blindness in children
Spark Therapeutics Reports 2016 Financial Results and Business HighlightsGlobeNewswire (press release)

all 2 news articles »

Continue reading

2017-02-22 NEWS

MIT News

3Q: US patent office’s ruling on CRISPR
MIT News
Q: What is CRISPR, and what research is being done at MIT and the Broad Institute? A: CRISPR is a naturally occurring system by which bacteria and other microorganisms fight viral infections. CRISPR systems, such as CRISPR-Cas9 and CRISPRCpf1, …
There is more to come in the CRISPR storyThe Hindu
KQED Future of YouKQED
Editing the future: A brief introduction to CRISPRLexology (registration)
IAM (registration) (blog)
all 32 news articles »
Continue reading

2017-02-22 NEWS

FierceBiotech

ImmusanT’s celiac disease immunotherapy passes first clinical test
FierceBiotech
ImmusanT’s big idea is to use a trio of three peptides as an immunotherapy that it hopes will encourage the T cells involved in the inflammatory reaction in celiac disease to become tolerant to gluten. After a first course to induce tolerance, the
ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2Business Wire (press release)

all 2 news articles »